| Literature DB >> 29213124 |
Andrew P Cope1, Michael R Barnes2, Alexandra Belson3, Michael Binks3, Sarah Brockbank4, Francisco Bonachela-Capdevila5, Claudio Carini6, Benjamin A Fisher7, Carl S Goodyear8, Paul Emery9, Michael R Ehrenstein10, Neil Gozzard11, Ray Harris12, Sally Hollis13, Sarah Keidel14, Marc Levesque14, Catharina Lindholm13, Michael F McDermott9, Iain B McInnes8, Christopher M Mela15, Gerry Parker11, Simon Read16, Ayako Wakatsuki Pedersen4, Frederique Ponchel9, Duncan Porter8, Ravi Rao3, Anthony Rowe5, Peter Schulz-Knappe17, Matthew A Sleeman18, Deborah Symmons19, Peter C Taylor20, Brian Tom21, Wayne Tsuji22, Denny Verbeeck5, John D Isaacs4.
Abstract
Collaboration can be challenging; nevertheless, the emerging successes of large, multi-partner, multi-national cooperatives and research networks in the biomedical sector have sustained the appetite of academics and industry partners for developing and fostering new research consortia. This model has percolated down to national funding agencies across the globe, leading to funding for projects that aim to realise the true potential of genomic medicine in the 21st century and to reap the rewards of 'big data'. In this Perspectives article, the experiences of the RA-MAP consortium, a group of more than 140 individuals affiliated with 21 academic and industry organizations that are focused on making genomic medicine in rheumatoid arthritis a reality are described. The challenges of multi-partner collaboration in the UK are highlighted and wide-ranging solutions are offered that might benefit large research consortia around the world.Entities:
Mesh：
Substances：
Year: 2017 PMID： 29213124 PMCID： PMC6711406 DOI： 10.1038/nrrheum.2017.200
Source DB: PubMed Journal: Nat Rev Rheumatol ISSN： 1759-4790 Impact factor: 32.286